Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events

Clinical Cardiology

Volumn 40, Issue 10, 2017, Pages 932-939

  Lemesle, Gilles ^a,b,c   Ducrocq, Gregory ^d,e,f   Elbez, Yedid ^d,e,f   Van Belle, Eric ^a,b,c   Goto, Shinya ^g   Cannon, Christopher P ^h   Bauters, Christophe ^b,c,i   Bhatt, Deepak L ^h   Steg, Philippe Gabriel ^d,e,f,j  

^a INSERM UMR 1011 ^*  (France)

^b UNIV LILLE   (France)

^c Parasitology Mycology   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Publics Assistance Paris Hospitals of Paris   (France)

^f Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^g TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ INSTITUT PASTEUR DE LILLE   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

Antiplatelet Therapy; Antithrombotic; Atrial Fibrillation; Bleeding; Coronary Artery Disease; Major Adverse Cardiovascular Events; Oral Anticoagulant

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; VITAMIN K GROUP;

AGED; AGING; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR DISEASE; CHA2DS2-VASC SCORE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; THROMBOSIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; HEART INFARCTION; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; ORAL DRUG ADMINISTRATION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; REGISTER; STATISTICAL MODEL; TIME FACTOR; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; VITAMIN K;

EID: 85022319674     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22750     Document Type: Article

References (35)

1. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354–e471.
2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–2104.
3. Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64:1430–1436.
4. Ruff CT, Bhatt DL, Steg PG, et al. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2014;170:413–418.
5. Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855–863, 863.e2.
6. Fauchier L, Greenlaw N, Ferrari R, et al. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY Registry. PLoS One. 2015;10:e0125164.
7. Steg PG, Greenlaw N, Tardif JC, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J. 2012;33:2831–2840.
8. Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16:308–319.
9. Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost. 2013;110:560–568.
10. Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155–3179.
11. Schurtz G, Bauters C, Ducrocq G, et al. Impact of the adjunction of aspirin on top of oral anticoagulants in stable coronary artery disease outpatients with an indication for anticoagulation. Panminerva Med. 2016;58:271–285.
12. Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. Thromb Haemost. 2010;104:657–663.
13. Steg PG, Bhatt DL. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. Eur Heart J Acute Cardiovasc Care. 2017;6:93–97.
14. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
15. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433–1441.
16. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189.
17. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350–1357.
18. Alberts MJ, Bhatt DL, Mas JL, et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30:2318–2326.
19. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206.
20. Ducrocq G, Wallace JS, Baron G, et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J. 2010;31:1257–1265.
21. Alberts MJ, Bhatt DL, Smith SC Jr, et al. Risk factors and outcomes for patients with vascular disease and serious bleeding events. Heart. 2011;97:1507–1512.
22. Parsons LS. Performing a 1:n case–control match on propensity score. Paper presented at: Twenty-Ninth Annual SAS Users Group International (SUGI) Conference; May 9–12, 2004; Montreal, Canada.
23. Aguilar E, Garcia-Diaz AM, Sanchez Munoz-Torrero JF, et al. Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation. Thromb Res. 2012;130:390–395.
24. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
25. Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014;35:224–232.
26. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
27. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
28. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634–640.
29. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
30. Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128:721–728.
31. Xu H, Ruff CT, Giugliano RP, et al. Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc. 2016;5(2).
32. Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014;129:1577–1585.
33. Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103:307–314.
34. De Caterina R, Ammentorp B, Darius H, et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart. 2014;100:1625–1635.
35. Huisman MV, Rothman KJ, Paquette M, et al. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69:777–785.